Figure 5

HDAC1 and HDAC6 drive invasiveness in an in vivo model of IDH1 mutant glioma. (A) 10,000 BT-142 cells infected with the following lentiviral constructs (shControl, shHDAC1, and shHDAC6) were implanted in the caudate of NSG mice and allowed to grow until symptoms developed (N = 5 per cohort). (B) Neurological symptoms were recorded (e.g. “Weight loss,” “Seizures”) and following development of symptoms, mice were euthanatized. Following euthanasia, the brains were removed, sectioned, stained with hematoxylin and eosin, and graded by a blinded neuropathologist (MH) for “Invasive,” “Non-Invasive,” or “No tumor seen”. (C) Representative sections are shown. (D) Given the important role of HDAC6 in IDH1 mutant gliomas, two HDAC6 inhibitors (10 μM Ricolinostat, 10 μM ACY-738) were tested on a panel of four IDH1 mutant glioma lines for 7 days to determine the effect on cell number.